Incyte
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 7 disclosed transactions, Incyte concentrates its licensing activity in Hematology, Oncology, and Dermatology. Incyte pays a 0.70x discount to market median. Their most common deal structure is Acquisition, with an average disclosed value of $1.4B. Most recent activity: 2026.
Pipeline coverage & gaps
Incyte has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 5 | $557M | $1.5B |
| License | 1 | $150M | $900M |
| Collaboration | 1 | $200M | $1.4B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Late-stage von Willebrand disease drug | Vega Therapeutics (Star Therapeutics) | von Willebrand disease / bleeding disorders | unknown | $1.3B | $2.0B |
| 2026 | Vega | Star Therapeutics | blood disorder | unknown | — | $2.0B |
| 2026 | factor VIII-independent bleeding disorder program | Vega Therapeutics | bleeding disorders | unknown | $730M | $2.0B |
| 2024 | EP262 and MRGPRX programs | Escient Pharmaceuticals | Atopic Dermatitis, Chronic Pruritus | phase_1 | $200M | $1.0B |
| 2024 | solid_tumors | MacroGenics | solid_tumors | phase_1 | $150M | $900M |
| 2024 | mds | Syndax Pharmaceuticals | mds | approved | $200M | $1.4B |
| 2023 | ATR | Mirati Therapeutics | Pancreatic | discovery | $46M | $490M |
How this is computed
For each Incyte deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.633, clamped to [0.7, 1.5].